SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Noven Pharmaceuticals (NOVN)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Just My Opinion who wrote (21)10/17/1997 12:38:00 PM
From: Todd D. Wiener   of 66
 
Would You Rather Die Than Go To The Dentist? Survey
Says You're Not Alone

PR Newswire - October 16, 1997 14:28

Pain-Free Alternative for Dental Procedures Launched at
ADA Meeting in Washington, D.C.

WASHINGTON, D.C., Oct. 16 /PRNewswire/ -- It's a fact -- many Americans
would rather "die" than go to the dentist. A recent study of dental attitudes
says nearly one in 10 people equate going to the dentist with fear of dying.
Researchers also found that about 50 percent of adults express some level of
anxiety when faced with a prospect of sitting in the dentist's chair,
according to the survey sponsored by Noven Pharmaceuticals, Inc.
Almost 80 percent of the 1,078 adult respondents said they would be more
willing to visit the dentist if there was a pain-free option available.
Dental phobics can relax. A new approach to reducing needle pain is now
available. DentiPatch(R) (lidocaine transoral delivery system), being
demonstrated at the American Dental Association (ADA) meeting in Washington,
D.C. (Oct. 18-22), offers safe localized numbing and may replace injections in
some procedures. DentiPatch(R), a small band-aid-like strip, is applied
directly onto the palate or gums and can be used for common soft-tissue dental
procedures such as scaling and root planing. The FDA has approved
DentiPatch(R) for marketing and is now available nationwide.
Noven Pharmaceuticals, Inc. (Nasdaq: NOVN) is an industry leader in the
development and commercialization of advanced drug-delivery systems. For more
information on DentiPatch(R) and Noven Pharmaceuticals, Inc. visit our Web
site at http//www.dentipatch.com.
Forward looking statements contained herein are qualified by and subject
to the risks and uncertainties specified by Noven in its most recent periodic
filings with the Securities and Exchange Commission.

SOURCE Noven Pharmaceuticals, Inc.
NOTE TO EDITOR: B-roll is available; Dr. Mark Slovin, an expert in the
field of DentoPhobia, is available for interviews; DentoPhobia, experienced by
approximately 45 million people in the United States, is extreme fear of
dental procedures; Dentists in your city who use DentiPatch(R) also are
available for interviews; The study was conducted by Noven Pharmaceuticals,
Inc. using a survey size of 1,078 with a margin of error of +\- 2.98 percent
in 95 out of 100 cases; Journalists attending the ADA Meeting, slated for Oct.
18-21, may try samples of DentiPatch(R) at booths 512 and 513 at the
Washington Convention Center
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext